Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosamprenavir/Ritonavir QD vs BID in HIV-1
NCT00450580Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Mar 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of fosamprenavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks. Started Mar 2007; status: completed.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00450580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450580.